NTLA Q2 2024 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-48.8% YoY

Gross Profit

$4M62.6% margin

Operating Income

-$139M-1998.6% margin

Net Income

-$147M-2112.6% margin

EPS (Diluted)

$-1.52

QoQ Revenue Growth

-76.0%

Cash Flow

Operating Cash Flow

-$58M

Free Cash Flow

-$59M

Stock-Based Comp.

$41M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$220M

Stockholders' Equity

$971M

Cash & Equivalents

$131M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$14M	-48.8%
Gross Profit	$4M	-$102M	+104.3%
Operating Income	-$139M	-$132M	-5.1%
Net Income	-$147M	-$124M	-18.8%